Biogeneric race in Europe heats up
Swiss biopharmaceutical firm Biopartners has got the thumbs up from the European Commission for its biosimilar drug Valtropin, making it only the second biogeneric drug to have been approved in Europe after Sandoz's Omnitrope received marketing...